Hepatic Disease in Patients With HIV

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 11/13/21 (What's New)

Summary

  • In persons coinfected with HIV and HCV, the prevalence of steatosis ranges from 40% to 70%, with higher rates observed among persons with significant hepatic fibrosis, HCV genotype 3, and exposure to NRTIs didanosine and stavudine[Macías 2012; Sulkowski 2005; Miller 2000; McGovern 2006; Marks 2005]
    • Since these drugs are no longer used, this risk is diminished compared with previous times. However, many older patients will undoubtedly have been exposed to these drugs in earlier regimens
  • Patients with HIV receiving ART may be at increased risk for the development of NAFLD, particularly in the setting of obesity

Action required